The genomic grade index (GGI) completes the prognostic value of histological grade (HG). Other proliferation markers include the mitotic activity index (MAI) and the Ki67 immunohistochemistry (IHC) status. We compared the prognostic value of GGI, HG, MAI, Ki67 IHC and messenger RNA (mRNA) status in node-positive breast cancer (BC) patients treated with adjuvant anthracycline-based chemotherapy in the prospective PACS01 trial.
introduction
The clinical outcome of early breast cancer (BC) patients is heterogeneous. The histological grade (HG) of tumours has long been a major prognostic feature [1] . Based on the microscopic semi-quantitative assessment of nuclear pleomorphism, tubule formation and mitotic count, it represents the morphological assessment of tumour biological characteristics and has three levels (HG1, HG2 and HG3). The Nottingham modification of the Scarff-Bloom-Richardson grading-the Elston-Ellis grading- [2, 3] has improved the interobserver reproducibility. Today, the HG is routinely used worldwide and adds important prognostic information to other significant but time-influenced parameters such as tumour size and lymph node status. However, some issues such as interobserver reproducibility, analysis of small biopsies or prognostic significance of HG2 remain problematic [4, 5] .
Recently, high-throughput molecular analyses have shown promise to improve prognostic classification [6] . The genomic grade (GG) is a 128-probe expression signature, which improves the accuracy of grading by resolving 80% of HG2 into GG-1 and GG-3 with low versus high risk of relapse, respectively [7] . The GG outperforms and completes the prognostic value of the HG in patients with or without adjuvant systemic therapy [7] [8] [9] . Most of the genes overexpressed in HG3 tumours are associated with the cell cycle and proliferation. The genomic grade index (GGI) is the continuous variable from which the GG-1/GG-3 classification is derived.
Other classical measurements of tumour cell proliferation include the mitotic activity index (MAI) and the expression of the Ki67 protein, measured using microscopic analysis and immunohistochemistry (IHC), respectively [10] [11] [12] [13] [14] [15] . The MAI is the most important prognostic component of HG [16] . Ki67 is expressed during the cell cycle and is the most extensively studied proliferation marker. The MKI67 gene is part of the GG signature. High MAI and high Ki67 IHC expression are associated with shorter survival in early BC [12, [16] [17] [18] . Whether one of them is superior to the other one in prognostic term remains unclear [12, [19] [20] [21] [22] [23] [24] [25] [26] . Both the measurements display some limitations that have impeded their routine clinical use [27] , and whether they provide additional prognostic information to commonly used prognostic indices remains unclear [18] .
Thus, like HG, GGI, MAI and Ki67 IHC have prognostic values in early BC. Surprisingly and although clinically relevant [12] , they have never been confronted all together in a prognostic analysis. The present study aimed at comparing the contribution of HG, GGI, MAI and Ki67 IHC and messenger RNA (mRNA) status to prognostication in early BC patients treated in the prospective UNICANCER PACS01 trial [28] . Notably, we aimed at determining whether the GGI provides independent and additional prognostic information to centrally assessed HG, MAI and Ki67 IHC status.
materials and methods

breast tumours
This study is ancillary to the PACS01 trial, a multicenter, prospective, phase III, open-label trial, which compared six cycles of fluorouracil, epirubicin and cyclophosphamide (FEC; A arm) with three cycles of FEC followed by three cycles of docetaxel (Taxotere, Sanofi-Aventis, Paris, France; FEC-D; B arm) as adjuvant chemotherapy in node-positive operable BC [28] . A total of 1999 patients were enrolled between 1997 and 2000. Postmenopausal women and premenopausal women from December 1998, with hormone-receptor (HR)-positive tumour [estrogen-receptor (ER) and/or progesterone-receptor (PR)-positive] received tamoxifen after chemotherapy. Radiotherapy was mandatory for all patients who had undergone breast-conservative surgery, and was recommended after mastectomy. No patient with HER2-positive tumour received adjuvant trastuzumab. The primary end-point was disease-free survival (DFS), defined as the time from randomisation until first event: relapse (local, regional or metastatic), contralateral BC or death from any cause. After a median follow-up of 95 months, the 5-year DFS was 76% in the whole population [28] .
For translational studies, tumour samples had been collected from operative specimens before any systemic therapy. Patients provided written informed consent, and the study was approved by the ethics committee/ institutional review board. A tumour block representative of the tumour was collected for 1190 patients, allowing a central review by pathologists to define the Elston-Ellis HG, the MAI and the IHC status of HR (ER and PR), HER2 and Ki67. The MAI was defined by counting the number of mitotic figures per mm 2 of consecutive invasive cellular area in the periphery of the tumour when performing the Elston-Ellis grading. IHC used ER, PR, Ki67 and HER2-specific antibodies as previously described [29, 30] . We considered ER and PR staining as positive when at least 1% of tumour cells were stained. For Ki67 (MiB1 clone Dako, Glosstrup, Denmark), the percentage of tumour cells (between 500 and 1000 cells were counted) with positive nuclear staining was evaluated within at least three high-power fields (×40 objective) representative of the whole slide staining, including the invasive edge of the tumour and avoiding to score only the hot spots. The HER2 status was evaluated with the Dako scale (HercepTest kit scoring guidelines, DakoCytomation, Copenhagen, Denmark) as reported [29] . Fluorescent in situ hybridisation (FISH) was done for the six cases with 2+ IHC score: a HER2/CEP17 ratio >2.2 defined amplification and HER2 positivity. For 246 of these patients (128 from A arm and 118 from B arm), a frozen tumour sample including >60% of tumour cells was available.
gene expression profiling and data analysis
Gene expression profiles of PACS01 tumours had been generated using DNA microarrays [31] [32] [33] . Among the 1190 tumours with centralised determination of HG, MAI and Ki67 IHC, the transcriptional profiles were available for 204 cases, which represent the population analysed in the present study. The profiles had been obtained using Affymetrix U133 Plus 2.0 chips (N = 132; Affymetrix, Santa Clara, CA) and Ipsogen DiscoveryChip cDNA microarrays (N = 72; Ipsogen, Marseille, France). Experiments were done as previously described [31] [32] [33] .
The GGI was computed as reported [7] , and analysed as a continuous value. We also analysed the prognostic value of MKI67 mRNA expression as a continuous value. To be comparable across our two datasets and to exclude bias from population heterogeneity, MKI67 expression levels were standardised within each set using expression values of HG1 and HG3 samples. MKI67 mRNA expression was measured by analysing the PID 212022_s_at Affymetrix probe set or the IMAGE:428545 cDNA clone for Ipsogen chips. As a control, we verified the correlation between our two platforms for GGI and MKI67 mRNA measurements in a personal series of 160 BCs previously hybridised; the Spearman rank correlation coefficient (rho) was 0.94 for GGI and 0.85 for MKI67 mRNA (data not shown). The molecular subtypes of tumours (supplementary Table S1 , available at Annals of Oncology online) were determined using the PAM50 predictor [34] .
To extend the comparison between the GGI and MKI67 mRNA, we collected public Affymetrix datasets from the GEO database (GSE1456 [35] , GSE11121 [36] , GSE4922 [37] , GSE2990 [7] , GSE7290 [38] , GSE25066 [39] , GSE21653) resulting in a total of 1599 invasive BCs with GGI score, MKI67 mRNA expression and histoclinical data (including DFS and HG) available for analysis (supplementary Table S2 , available at Annals of Oncology online). The MAI and Ki67 IHC status were not available.
statistical analyses
This retrospective study is based on a prospective, multicentric dataset provided by the PACS01 trial. Distributions of molecular markers and categorical histoclinical variables were compared between groups using the Fisher exact test and Student t-test. Correlations between continuous values were measured using the Mann-Whitney test. The prognostic performance of GGI and the other four proliferation-related parameters was assessed in the overall population and the subset of HG2 patients. The primary endpoint was DFS. Data concerning patients without any event at last followup were censored. The follow-up was calculated from the date of randomisation to the time of first event or the time of last follow-up for censored patients. Kaplan-Meier survival curves were compared by a logrank test. Univariate and multivariate prognostic analyses were applied. First, we compared the prognostic value of GGI with that of HG, MAI and original articles 
results
PACS01 trial subpopulation
Gene expression profiles and centrally determined HG, MAI and Ki67 IHC expression were available for 204 cases (Table 1) . Fifty-six events were reported with a median timeto-event of 34 months (range 5-110). The median follow-up for the 148 event-free patients was 95 months (range 5-123).
The 5-year DFS was 77% (95% CI 72-83). For the 95 patients with an HG2 tumour, the median follow-up was 96 months (range 58-123) and 22 events were reported with a median time-to-event of 33 months (range 11-97). The 5-year DFS was 83% (95% CI 76-91). Histoclinical features of PACS01 patients included in our study and of those not included were similar (data not shown).
proliferation-related parameters and histoclinical correlations
Forty-five out of the 204 tumours were HG1, 95 were HG2 and 64 were HG3. The GGI values ranged from −1.85 to 2.74 (median = 0.11), and MKI67 mRNA expression from −4.45 to 3.25 (median = − .19). Ki67 IHC values ranged from 0% to 90% of positively stained tumour cells (median = 10%), and the MAI from 0 to 51 mitoses per mm 2 (median value = 8). As expected, positive correlations were found between the five parameters ( Figure 1A) . However, the degree of correlation varied: the parameter that overall correlated the most with all others was GGI, followed by MAI.
We also compared the correlations of these features with histoclinical features ( Figure 1B) . As expected and for all parameters, higher proliferation ( positive Student's t-values) was associated with HR-negative status, HER2-positive status and poor-prognosis molecular subtypes (basal, HER2-overexpressing and luminal B). However, here also, the degree of correlation varied according to the parameters: the GGI displayed the strongest correlations, whereas the Ki67 IHC status showed the lowest ones, inferior to those observed with the MAI.
prediction of the DFS-5 status
We analysed the correlation of the five proliferation-related parameters with the DFS status censored at 5 years (DFS-5). Out of the 204 patients, 46 displayed an event before 5 years Table 2 . The GGI showed the highest value (0.76) and the Ki67 IHC status the lowest one (0.58). Univariate and multivariate analyses were done ( Table 2 ). All parameters were significant in univariate analysis, with GGI showing the highest prognostic power (P = 2.41E − 06). In multivariate analysis including all variables, the GGI remained the sole prognostic factor (P = 7.58E − 04). The same analysis was applied to HG2 samples (N = 95; 14 events before 5 years; Table 2 ). In univariate (P = 3.73E − 03) and multivariate analyses (P = 5.23E − 03), the GGI was the only significant predictor.
univariate and multivariate Cox analyses for DFS
The same comparison was done using Cox regression analyses (Table 3 ). In the whole population, all variables were associated with DFS. However, in multivariate analysis, the GGI was the only significant parameter (HR = 1.60, P = 2.30E − 02). In the HG2 subgroup, the GGI was the only significant predictor in univariate (HR = 1.58, P = 1.96E − 02) and multivariate analyses (HR = 2.28, P = 7.10E − 03). These results suggested that the GGI was a better prognosticator than other proliferation-related variables in all 204 patients and in HG2 patients.
We then compared the prognostic value of GGI with that of other prognostic factors in the whole series of samples (Table 4) . Univariate analysis identified six factors associated with DFS (P < 0.05, Wald test): pT, pN, ER, PR and HER2 IHC status, and GGI. In multivariate analysis, only GGI remained significant (HR = 1.45, P = 8.50E − 03).
Of note, multivariate analyses comparing GGI with the proliferation-related parameters, then with the other prognostic factors, but stratified for the IHC-defined molecular subtypes (HR+/HER2−, HR−/HER2+ and HR−/HER2−) showed similar results: the GGI remained the only significant predictor (data not shown).
Comparison of GGI and MKI67 mRNA expression in a meta-analysis
We analysed a public gene expression dataset (N = 1599) to compare the prognostic values of GGI and MKI67 mRNA expression as continuous values in a large series (Table 5) . A strong correlation existed between the two parameters (Spearman rho = 0.76). However, it was not perfect, raising the possibility of a differential prognostic impact. The GGI and MKI67 expression strongly correlated with DFS in univariate analysis. In multivariate analysis, the GGI outperformed MKI67 mRNA expression (HR = 1.36, P = 2.00E − 10). The same analysis applied to the 656 HG2 samples found similar results with stronger and independent prognostic values for the GGI (HR = 1.555, P = 6.50E − 06). original articles
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The proliferation level of tumours is an important predictor of survival in BC [41, 42] . It has been assessed for many years by different parameters such as HG, MAI and Ki67 IHC status [12] . But HG displays some predictive imperfections, whereas the MAI and Ki67 IHC status display some technical limitations [13, 15, 27, 41, 43] . Proliferation is the common driving force responsible for several promising prognostic gene expression signatures [44] [45] [46] . The GGI, a score based on the combined expression of several cell cycle-related genes, outperforms the prognostic value of HG. But no head-to-head Results of multivariate analysis were similar when the pN status was analysed as a continuous value. GGI, genomic grade index; HR, hazard ratio.
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comparison of prognostic performances of GGI and HG, MAI and Ki67 IHC has been reported. We took advantage of the availability of a centralised histological reading and of gene expression dataset of 204 BC samples from patients treated in a prospective randomised trial of adjuvant chemotherapy. Our subpopulation was representative of the whole trial population, in which the Ki67 IHC binary status has both prognostic value [30] and predictive value for docetaxel benefit [29, 30] . Here, the tested variables were analysed as continuous rather than discrete values to avoid the delicate and unsolved dilemma of cut-off for Ki67 and MAI.
Despite the limited sample size, we showed that, among the five proliferation-related parameters, the GGI was the one that overall correlated most with the other ones and with the main biological features of BC (HR, HER2 and molecular subtypes). More importantly, regarding the prognostic performances, the GGI outperformed the four other parameters in the whole population for the DFS-5 status and the DFS, suggesting that its prognostic value is not time-related, at least until an 8-year follow-up. In HG2 patients, the GGI was the sole significant prognostic variable, performing better than the MAI and Ki67 IHC [21, 22, 47] . Finally, the GGI confirmed its independent prognostic value when compared with classical prognostic features. This prognostic value of GGI remained in multivariate analysis adjusted for the molecular subtypes, suggesting independency from this parameter. We also compared the prognostic performances of GGI with those of the modified SBR (mSBR) grading [47] , based upon the nuclear pleomorphism and mitotic index, and were also able to discriminate prognostic subgroups among Scarff-BloomRichardson (SBR) HG2 patients [47] . Interestingly, the GGI performed better than the mSBR in the whole series and in HG2 patients, both in univariate and multivariate analyses (data not shown). Of note, all these prognostic performances of GGI were retained when we used metastasis-free survival rather than DFS as an end-point (data not shown). Thus, our results confirm previous observations [7, 9] , but also suggest for the first time the prognostic dominance of GGI over other proliferation-related parameters.
This superiority of GGI in terms of correlations and of prognostic value may suggest that it is biologically more coherent than HG, MAI and Ki67 IHC status to capture the proliferation level of tumours. This may be due, at least in part, to its more quantitative aspect and to its more objective character. Indeed, Ki67 IHC and MAI are variable, mainly because of several scoring methods and a lack of technical standardisation [13, 43] , and today are not recommended for routine use [13, 15, 27, 41, 48] . Interobserver variations have been reported for HG, which remains the reference method to grade tumours. Another likely reason of GGI superiority is its combinatory multigene nature as shown by our comparative meta-analysis with MKI67 mRNA expression.
Our study presents several strengths. First, this is the first comparative study of microarray expression data and histological data regarding the prognostic value of proliferation-related parameters. Second, the data come from a randomised prospective clinical trial. Third, the histological proliferation-related parameters (HG, MAI and Ki67 IHC status) were centrally scored using international recommendations [47] . Fourth, the potential sources of heterogeneity (two different microarray platforms and a multicentric series of samples with heterogeneous conditions of acquisition and handling) did not alter the GGI performance. Conversely, the two main limitations are those of any retrospective subset biomarker study reported in adjuvant trials, the absence of initial formal assessment of statistical power and the limited proportion of available samples (10% here). Fortunately, the strong prognostic power of proliferation, and notably GGI, allowed significant results. Another limitation is the risk of false-positive results, intrinsic to unplanned analyses. We have planned to test the validity of our results in the series of 1190 formalin-fixed paraffinembedded and histologically reread PACS01 samples by using the GG qRT-PCR version [49] . In addition, we will search for a possible interaction between the GGI and docetaxel benefit, and will compare it with that observed with the Ki67 IHC status [29, 30] . Another perspective for clinical application will be to develop a GGI-based classifier to define high-risk versus low-risk tumours, rather than using continuous values. For example, in our series, the Cox model identified two GGIbased groups with different 5-year DFS (P < 0.001, log-rank test): 89% in the low-risk group (GGI-low, N = 109) and 64% in the high-risk group (GGI high, N = 95). However, a larger series is warranted to define an optimal cut-off using independent learning and validation sets. Finally, another limitation is the exclusive presence of patients with a lymph node-positive tumour.
In conclusion, our results suggest that the GGI could outperform the prognostic performances of proliferationrelated parameters (HG, MAI, Ki67 IHC and mRNA expression). Further validation is warranted in larger series, which will allow defining more precisely the additional prognostic value and the cost benefit of GGI compared with histoclinical features including those associated with cell proliferation [4] .
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